Mon 5/25/2020 08:16 ET
DJIA24465.169.790.04%TELCO163.610.670.41%GOLD1727.907.600.44%Shanghai2817.974.230.15%
S&P 5002955.457.090.24%BANKS310.942.710.87%OIL33.480.230.69%BITCOIN8752.1510.500.12%
NASDAQ9324.5940.100.43%PHARM600.103.600.60%US/EU1.090.000.00%Futures2980.8828.020.94%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - DermTech - DMTK   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DMTK
  
From: jonnyb (Rep: 94) reply to SunTzu772Date: 01/17/2020 10:16
Forum: DermTech - Msg #149Thread #674117356 (Rec: 0)
News is sinking in. Potential new SOC, this year’s revs could be huge. Re: DermTech Enters into Commercial and Medicare Advantage Payor Coverage Contrac...

Sent from my IPhone



Reply to SunTzu772 - Msg #2811729 - 01/16/2020 18:42

DermTech Enters into Commercial and Medicare Advantage Payor Coverage Contract for the Pigmented Lesion Assay => First coverage contract for the PLA the soon to be new SOC in Skin cancer detection -

January 16, 2020 5:45pm

DermTech, Inc. (NASDAQ:DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has contracted with a regional health plan to make DermTech's gene expression based Pigmented Lesion Assay ("PLA") for the early detection of melanoma available to the regional health plan's commercial and Medicare Advantage membership. This is the first contract with this health plan that provides coverage for the PLA.

DermTech's PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value ("NPV"), meaning there is a less than 1% chance of the PLA missing a melanoma when administered properly.

"We are excited to announce that our test is now available to a segment of commercial and Medicare Advantage members. Our PLA test offers significant benefits in early melanoma detection and reduced biopsies of benign lesions while also reducing costs to the healthcare system," said Dan Visage, Senior Vice President of Payor Access.

https://www.benzinga.com/pressreleases/20/01/b15139696/dermtech-enters-into-commercial-and-medicare-advantage-payor-coverage-contract-for-the-pigmented-l
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser jonnyb: Reward | Watch | IgnoreDMTK: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DMTK
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.